Prevalence and clinical significance of nonorgan specific antibodies in patients with autoimmune thyroiditis as predictor markers for rheumatic diseases

被引:28
|
作者
Elnady, Basant M. [1 ,2 ]
Kamal, Naglaa M. [3 ,4 ]
Shaker, Raneyah H. M. [5 ]
Soliman, Amal F. [1 ]
Hasan, Waleed A. [1 ]
Alghamdi, Hamed A. [4 ,6 ]
Algethami, Mohammed M. [7 ,8 ]
Jajah, Mohamed Bilal [7 ,8 ]
机构
[1] Benha Univ, Benha Fac Med, Dept Phys Med & Rheumatol, Banha, Egypt
[2] Alhada Armed Forces Hosp, Dept Rheumatol, At Taif, Saudi Arabia
[3] Cairo Univ, Dept Pediat & Pediat Hepatol, Fac Med, Cairo, Egypt
[4] Alhada Armed Forces Hosp, Dept Pediat, At Taif, Saudi Arabia
[5] Benha Univ, Benha Fac Med, Dept Publ Hlth, Banha, Egypt
[6] Armed Forces Hosp, At Taif, Saudi Arabia
[7] Al Hada Armed Forces Hosp, Dept Pulmonol, At Taif, Saudi Arabia
[8] Al Hada Armed Forces Hosp, Dept Endocrinol, At Taif, Saudi Arabia
关键词
antidouble-stranded DNA; antiextractable-nuclear antigens; antinuclear antibodies; autoimmune thyroid diseases; rheumatoid factor; anticyclic-citrullinated peptides; SYSTEMIC-LUPUS-ERYTHEMATOSUS; AMERICAN-COLLEGE; MUSCULOSKELETAL CONDITIONS; CLASSIFICATION CRITERIA; AUTOANTIBODIES; ARTHRITIS; ASSOCIATIONS; DISORDERS; BURDEN; HEALTH;
D O I
10.1097/MD.0000000000004336
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Autoimmune diseases are considered the 3rd leading cause of morbidity and mortality in the industrialized countries. Autoimmune thyroid diseases (ATDs) are associated with high prevalence of nonorgan-specific autoantibodies, such as antinuclear antibodies (ANA), antidouble-stranded deoxyribonucleic acid (anti-dsDNA), antiextractable-nuclear antigens (anti-ENAs), rheumatoid factor (RF), and anticyclic-citrullinated peptides (anti-CCP) whose clinical significance is unknown.We aimed to assess the prevalence of various nonorgan-specific autoantibodies in patients with ATD, and to investigate the possible association between these autoantibodies and occurrence of rheumatic diseases and, if these autoantibodies could be considered as predictor markers for autoimmune rheumatic diseases in the future.This study had 2 phases: phase 1; in which 61 ATD patients free from rheumatic manifestations were assessed for the presence of these nonorgan-specific autoantibodies against healthy 61 control group, followed by 2nd phase longitudinal clinical follow-up in which cases are monitored systematically to establish occurrence and progression of any rheumatic disease in association to these autoantibodies with its influences and prognosis.Regarding ATD patients, ANA, anti-dsDNA, Anti-ENA, and RF were present in a percentage of (50.8%), (18%), (21.3%), and (34.4%), respectively, with statistically significance difference (P<0.5) rather than controls. Nearly one third of the studied group (32.8%) developed the rheumatic diseases, over 2 years follow-up. It was obvious that those with positive anti-dsDNA had higher risk (2.45 times) to develop rheumatic diseases than those without. There was a statistically significant positive linear relationship between occurrence of disease in months and (age, anti-dsDNA, anti-CCP, RF, and duration of thyroiditis). Anti-dsDNA and RF are the most significant predictors (P<0.0001).ATD is more associated with rheumatic diseases than previously thought. Anti-dsDNA, RF, and anti-CCP antibodies may be used as predictive screening markers of systemic lupus erythematosus and RA, with early referral to rheumatologists for close follow-up and early diagnoses for appropriate disease management of the disease, as early disease control will allow better quality of life.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Association between clinical phenotypes of dermatomyositis and polymyositis with myositis-specific antibodies and overlap systemic autoimmune diseases
    Chiang, Hui-Ling
    Tung, Chien-Hsueh
    Huang, Kuang-Yung
    Hsu, Bao-Bao
    Wu, Cheng-Han
    Hsu, Chia-Wen
    Lu, Ming-Chi
    Lai, Ning-Sheng
    MEDICINE, 2021, 100 (37)
  • [22] Anti-DFS70/LEDGF Antibodies Are More Prevalent in Healthy Individuals Compared to Patients with Systemic Autoimmune Rheumatic Diseases
    Mahler, Michael
    Parker, Todd
    Peebles, Carol L.
    Andrade, Luis E.
    Swart, Andreas
    Carbone, Yvette
    Ferguson, David J.
    Villalta, Danilo
    Bizzaro, Nicola
    Hanly, John G.
    Fritzler, Marvin J.
    JOURNAL OF RHEUMATOLOGY, 2012, 39 (11) : 2104 - 2110
  • [23] Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseases
    Ghanem, Paola
    Murray, Joseph C.
    Marrone, Kristen A.
    Scott, Susan C.
    Feliciano, Josephine L.
    Lam, Vincent K.
    Hann, Christine L.
    Ettinger, David S.
    Levy, Benjamin P.
    Forde, Patrick M.
    Shah, Ami A.
    Mecoli, Christopher
    Brahmer, Julie
    Cappelli, Laura C.
    RMD OPEN, 2023, 9 (04):
  • [24] Prevalence of anti-dense fine speckled 70 antibodies in healthy individuals and patients with antinuclear antibody-associated autoimmune rheumatic diseases in Japan
    Hayashi, Nobuhide
    Uto, Kenichi
    Imanishi, Akiko
    Sugiyama, Daisuke
    Morinobu, Akio
    Saegusa, Jun
    MEDICINE, 2021, 100 (09) : E24556
  • [25] Low Prevalence of Anti-DFS70/LEDGF Antibodies in Patients with Dermatomyositis and Other Systemic Autoimmune Rheumatic Diseases Reply
    Mahler, Michael
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (01) : 94 - 95
  • [26] Anticyclic Citrullinated Peptide Antibodies in Patients with Rheumatic Diseases other than Rheumatoid Arthritis: Clinical or Pathogenic Significance?
    Caterbi, Sara
    Bistoni, Onelia
    Alunno, Alessia
    Bartoloni, Elena
    Gerli, Roberto
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (06) : 1063 - U192
  • [27] Prevalence of thyroid autoantibodies in patients with systematic autoimmune rheumatic diseases. Cross-sectional study
    Posselt, Rayana Taques
    Coelho, Vinicius Nicolelli
    Pigozzo, Danieli Cristina
    Guerrer, Marcela Idalia
    Fagundes, Marilia da Cruz
    Nisihara, Renato
    Skare, Thelma Larocca
    SAO PAULO MEDICAL JOURNAL, 2017, 135 (06): : 535 - 540
  • [28] Detection of multiple myositis-specific antibodies: prevalence and clinical significance
    Jerbi, Ameni
    Karoui, Sahar
    Snoussi, Mouna
    Feki, Sawsan
    Damak, Chifa
    Bahloul, Zouheir
    Masmoudi, Hatem
    Marzouk, Sameh
    Hachcicha, Hend
    LABORATORY MEDICINE, 2025,
  • [29] Clinical significance of serum thrombomodulin levels in patients with systemic rheumatic diseases
    Kotajima, L
    Aotsuka, S
    Sato, T
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1997, 15 (01) : 59 - 65
  • [30] Anti-Ro52/TRIM21 antibodies are associated with aberrant inflammatory circuits in patients with systemic autoimmune rheumatic diseases
    Amezcua-Guerra, Luis M.
    Perez-Garcia, Luis F.
    Jimenez-Rojas, Valentin
    Marquez-Velasco, Ricardo
    Silveira, Luis H.
    GACETA MEDICA DE MEXICO, 2023, 159 (01): : 56 - 65